Trending...
- Assymetrix Launches the Deepest Independent Prediction Market Data API
- Resident Inspect Joins Property Meld Nexus Network with API Integration
- CCHR: 'Plant-Based' Psychedelics Push Masks Synthetic Drugs and Billion-Dollar Profits
PHILADELPHIA, Nov. 21, 2023 /PRNewswire/ -- A securities fraud lawsuit has been filed against ACELYRIN, Inc. ("Acelyrin") (NASDAQ: SLRN). The lawsuit is captioned Aramouni v. Acelyrin, Inc., No. 2:23-cv-09672 (C.D. Cal.), and is filed on behalf of purchasers of Acelyrin's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period").
CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT.
Investors who purchased or acquired Acelyrin securities during the Class Period may, no later than January 16, 2024, seek to be appointed as a lead plaintiff representative of the class.
The complaint alleges that, throughout the Class Period, the defendants made failed to disclose that: (i) izokibep was less effective in treating Hidradenitis Suppurativa than defendants had led investors to believe; (ii) accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects; and (iii) as a result, Acelyrin also overstated the company's business prospects post-IPO.
More on The PennZone
For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at [email protected] or (267) 637-3176, or Andrew Abramowitz at [email protected] or (215) 875-3015 or CLICK HERE.
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.
More on The PennZone
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
Contacts:
James Maro, Senior Counsel
Berger Montague
(267) 637-3176
[email protected]
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
SOURCE Berger Montague
CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT.
Investors who purchased or acquired Acelyrin securities during the Class Period may, no later than January 16, 2024, seek to be appointed as a lead plaintiff representative of the class.
The complaint alleges that, throughout the Class Period, the defendants made failed to disclose that: (i) izokibep was less effective in treating Hidradenitis Suppurativa than defendants had led investors to believe; (ii) accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects; and (iii) as a result, Acelyrin also overstated the company's business prospects post-IPO.
More on The PennZone
- Flamingo Compliance Launches Schengen Area Trip Planning Tools as New Digital Border Controls Take Effect
- HHS Announces Major Push to Address Psychiatric Drug Risks: CCHR Applauds Focus on Informed Consent and Safe Tapering
- PhaseZero Launches Eight AI Agents for Manufacturers and Distributors - Connecting Sales, Support, and Operations Teams Across Full Commerce Journey
- @tickerbitcoinbb and @girl_still_cute Announce the Arrival of SPROTO AEON BABY 1.0 – A New Chapter for the HarryPotterObamaSonic10Inu Universe
- Michigan Fitness Foundation Gifts EPEC Moves K–5 PE Curriculum Program to Educators during Michigan Moves Month
For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at [email protected] or (267) 637-3176, or Andrew Abramowitz at [email protected] or (215) 875-3015 or CLICK HERE.
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.
More on The PennZone
- Sidow Sobrino, the One and Only World's No.1 Superstar®, Launches Dangerous Joy
- Modern Site Builders Launches WolfResume.com, an AI Career Kit Built for ATS Hiring
- Slotozilla Expands Bonus Portfolio and Affiliate Reach Following iGB Barcelona 2026
- ThoroughCare Expands Remote Patient Monitoring with Withings Integration
- Wellsboro Earns Gold Bird Town Certification, Highlighting Conservation Leadership
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
Contacts:
James Maro, Senior Counsel
Berger Montague
(267) 637-3176
[email protected]
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
SOURCE Berger Montague
Filed Under: Business
0 Comments
Latest on The PennZone
- Resident Inspect Joins Property Meld Nexus Network with API Integration
- Premiere Venue Group Announces $25,000 Sponsorship to Support Ann's Heart Programs and Events
- L2 Aviation Awarded IDIQ Contract by the U.S. Army for M1A2 Abrams Tank
- Sycor.Rental Named Among 2026 Best Microsoft Dynamics ERP Supply Chain Solutions
- KDG Redefines Enterprise Software Development with AI-Assisted and Agentic Delivery Model
- Beyond Medication: Kellyn Foundation And Highmark Wholecare Tackle Type 2 Diabetes, Obesity With Comprehensive Lifestyle Program
- TrueNorth Wellness Services Raises $10,066 During Give Local York 2026
- Smart Tools App Brings 100+ Everyday Utilities Into One Android Solution
- Veikkaus Appoints New CFO as Finland's Gambling Monopoly Braces for Breakup
- Philadelphia's First Ginger Store Honored With City Citation for Nine Years of Health and Wellness
- ICTPBX Released: White-Label, Multi-Tenant Open Source PBX Platform for ITSPs
- 5,521 College Athletes Launch Own Merch Stores in Just 30 Days on AthleteMerch.com, Reaching 7,975 Live Storefronts Nationwide
- Altruvest and Financial Executives International Canada Announce Strategic Partnership to Strengthen Nonprofit Boards Across Canada
- Dr. Dee for the People: A Vision of Hope, Healing, and Transformation for Philadelphia
- Free Critical Illness Claim Calculator Launches to the Public
- Best Companies Group Launches Free Best Banks to Work For Program
- I Voted Tvocracy and I Voted Radiocracy
- Tolle Lege Learning Launches Publishing House to Revolutionize Early Learning Initiatives
- HRC Fertility Celebrates Beverly Hills Grand Opening, Spotlighting Fertility Care as Women's Health Month Begins
- HRC Fertility's Dr. Christo G. Zouves Appointed to San Mateo County Medical Association Board of Directors